TFS Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

TFS Capital’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-53,768	Closed	-$689K	–	756
2016 Q4	$689K	Buy	+53,768	New	+$679K	0.18%	174
2016 Q3	–	Sell	-75,113	Closed	-$823K	–	862
2016 Q2	$823K	Buy	+75,113	New	+$734K	0.15%	224
2016 Q1	–	Sell	-60,819	Closed	-$590K	–	1045
2015 Q4	$590K	Buy	+60,819	New	+$588K	0.06%	385
2015 Q3	–	Sell	-117,474	Closed	-$1.19M	–	970
2015 Q2	$1.19M	Buy	+117,474	New	+$1.37M	0.12%	290
2014 Q4	–	Sell	-76,572	Closed	-$831K	–	1069
2014 Q3	$831K	Buy	76,572 +21,030	+38%	+$241K	0.07%	439
2014 Q2	$713K	Buy	+55,542	New	+$604K	0.06%	525

Other funds holding IRWD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TFS Capital's IRWD Position: Q1 2017 in Review

TFS Capital sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2017, closing a stake of 53,768 shares — an estimated $689K sold.

TFS Capital first reported a position in IRWD in Q2 2014 and held it in 6 quarters. The position peaked at $1.19M in Q2 2015. 162 funds tracked by Wall St. Rank hold IRWD as of Q1 2017.

TFS Capital reported no remaining Ironwood Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
TFS Capital sold 53,768 Ironwood Pharmaceuticals shares in Q1 2017, an estimated $689K.
TFS Capital first reported a position in Ironwood Pharmaceuticals in Q2 2014 and held it in 6 quarters.
TFS Capital's Ironwood Pharmaceuticals position peaked at $1.19M in Q2 2015.
162 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.